Novus Therapeutics, Inc. (NVUS) At $3.90 Forms Bottom; Kempharm (KMPH) Shorts Down By 6.11%

Kempharm Incorporated (NASDAQ:KMPH) had a decrease of 6.11% in short interest. KMPH’s SI was 255,100 shares in January as released by FINRA. Its down 6.11% from 271,700 shares previously. With 24,200 avg volume, 11 days are for Kempharm Incorporated (NASDAQ:KMPH)’s short sellers to cover KMPH’s short positions. The SI to Kempharm Incorporated’s float is 3.31%. The stock increased 10.69% or $0.545 during the last trading session, reaching $5.645. About 159,574 shares traded or 297.02% up from the average. KemPharm, Inc. (NASDAQ:KMPH) has declined 32.16% since January 19, 2017 and is downtrending. It has underperformed by 48.86% the S&P500.

Novus Therapeutics, Inc. (NVUS) formed multiple bottom with $3.74 target or 4.00% below today’s $3.90 share price. Novus Therapeutics, Inc. (NVUS) has $27.63 million valuation. The stock increased 1.83% or $0.07 during the last trading session, reaching $3.9. About 7,771 shares traded. Novus Therapeutics, Inc. (NASDAQ:NVUS) has 0.00% since January 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 15 analyst reports since August 14, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 17 by Canaccord Genuity. Oppenheimer maintained the stock with “Outperform” rating in Friday, September 18 report. Canaccord Genuity maintained the stock with “Buy” rating in Monday, September 11 report. The stock of KemPharm, Inc. (NASDAQ:KMPH) earned “Buy” rating by RBC Capital Markets on Tuesday, January 16. The rating was maintained by Oppenheimer on Thursday, August 10 with “Buy”. The stock of KemPharm, Inc. (NASDAQ:KMPH) has “Buy” rating given on Wednesday, June 28 by Roth Capital. RBC Capital Markets maintained the shares of KMPH in report on Friday, May 6 with “Outperform” rating. The firm earned “Buy” rating on Tuesday, December 20 by Canaccord Genuity. Canaccord Genuity maintained KemPharm, Inc. (NASDAQ:KMPH) on Thursday, August 10 with “Buy” rating. As per Friday, August 14, the company rating was maintained by RBC Capital Markets.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $82.74 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: